SAGE-217, a novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase i dose-finding studies.
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
SAGE-217, a novel γ-aminobutyric acid A (GABA A ) receptor positive allosteric modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) studies to assess the safety and pharmacokinetics (PK) of SAGE-217 following administration as an oral solution. In the SAD study, subjects were randomized 6:2 to a single dose of SAGE-217 or placebo. Doses ranged from 0.25 to 66 mg across nine cohorts. In the MAD study, subjects were randomized 9:3 and received SAGE-217 (15, 30, or 35 mg) or placebo once daily for 7 days. In both studies, PK, maximum tolerated dose (MTD; against predetermined criteria), safety, and tolerability were assessed. A total of 108 healthy volunteers enrolled in the studies—72 subjects in the SAD study and 36 subjects in the MAD study. SAGE-217 was orally bioavailable, with a terminal-phase half-life of 16–23 h and a t max of approximately 1 h. The MTDs for the oral solution of SAGE-217 in the SAD and MAD studies were determined to be 55 and 30 mg daily, respectively. In both studies, SAGE-217 was generally well tolerated, and no serious adverse events (SAEs) were reported. Most AEs were mild, dose-dependent, transient, occurred around the t max , and related to drug pharmacology. SAGE-217 was generally well tolerated, and its PK profile was well characterized. Based on this profile, SAGE-217 has been advanced into multiple phase II clinical programs and pivotal studies of major depressive disorder and postpartum depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Zuranolone (SAGE-217; Sage Therapeutics, Inc) is an investigational NAS GABAAR PAM with a similar mechanism of action and a pharmacokinetic profile suitable for once-daily oral dosing.39”
From Effect of Zuranolone vs Placebo in Postpartum Depression (2021) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“NAS GABAAR PAMs have pharmacological profiles and binding sites distinct from benzodiazepines,40,41 with the ability to modulate the activity of both synaptic and extrasynaptic GABAARs.39,42”
From Effect of Zuranolone vs Placebo in Postpartum Depression (2021) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Quantification of Sleepiness: A New Approach
Hoddes, E., Zarcone, V., Smythe, H., Phillips, R., & Dement, W. C. (1973) · Psychophysiology · doi:10.1111/j.1469-8986.1973.tb00801.x · Cited by 2,538
Validity and Reliability of the Observer??s: Assessment of Alertness/Sedation Scale
CHERNIK, D. A., GILLINGS, D., LAINE, H., HENDLER, J., SILVER, J. M., DAVIDSON, A. B., SCHWAM, E. M., & SIEGEL, J. L. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199008000-00003 · Cited by 1,246
The GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
GABAergic Mechanisms in Epilepsy
Treiman, D. M. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.042suppl.3008.x · Cited by 836
Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31551-4 · Cited by 795
Self-citationBrexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., Doherty, J., Epperson, C. N., Deligiannidis, K. M., Riesenberg, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31264-3 · Cited by 479
Self-citationLener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468
Extrasynaptic GABA A Receptors: Form, Pharmacology, and Function
Belelli, D., Harrison, N. L., Maguire, J., Macdonald, R. L., Walker, M. C., & Cope, D. W. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3340-09.2009 · Cited by 464
The role of reproductive hormones in postpartum depression
Schiller, C. E., Meltzer-Brody, S., & Rubinow, D. R. (2015) · CNS Spectrums · doi:10.1017/s1092852914000480 · Cited by 451
GABAAR Plasticity during Pregnancy: Relevance to Postpartum Depression
Maguire, J., & Mody, I. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.019 · Cited by 437
Confidence Interval Criteria for Assessment of Dose Proportionality
Smith, B. P., Vandenhende, F. R., DeSante, K. A., Farid, N. A., Welch, P. A., Callaghan, J. T., & Forgue, S. T. (2000) · Pharmaceutical Research · doi:10.1023/a:1026451721686 · Cited by 356
Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders
Mignot, E., Taheri, S., & Nishino, S. (2002) · Nature Neuroscience · doi:10.1038/nn944 · Cited by 353
The role of allopregnanolone in depression and anxiety
Schüle, C., Nothdurfter, C., & Rupprecht, R. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.09.003 · Cited by 312
Modulation of Vigilance in the Primary Hypersomnias by Endogenous Enhancement of GABA A Receptors
Rye, D. B., Bliwise, D. L., Parker, K., Trotti, L. M., Saini, P., Fairley, J., Freeman, A., Garcia, P. S., Owens, M. J., Ritchie, J. C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004685 · Cited by 168
Molecular targets in the treatment of anxiety
Kent, J. M., Mathew, S. J., & Gorman, J. M. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01672-4 · Cited by 167
Lambert, J. J., Belelli, D., Harney, S. C., Peters, J. A., & Frenguelli, B. G. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00124-2 · Cited by 164 · cited 1×
“Some endogenous NASs, such as the progesterone metabolite allopregnanolone, can potently modulate neuronal excitability, primarily through positive allosteric modulation of synaptic and extrasynaptic GABAA receptors [13, 14].”
BackgroundDeligiannidis, K. M., Sikoglu, E. M., Shaffer, S. A., Frederick, B., Svenson, A. E., Kopoyan, A., Kosma, C. A., Rothschild, A. J., & Moore, C. M. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.02.010 · Cited by 155
Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression
Kanes, S. J., Colquhoun, H., Doherty, J., Raines, S., Hoffmann, E., Rubinow, D. R., & Meltzer-Brody, S. (2017) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2576 · Cited by 151
Self-citationGABAergic Control of Depression-Related Brain States
Luscher, B., & Fuchs, T. (2015) · Advances in Pharmacology · doi:10.1016/bs.apha.2014.11.003 · Cited by 149
GABAergic Dysfunction in Essential Tremor: An11C-Flumazenil PET Study
Boecker, H., Weindl, A., Brooks, D. J., Ceballos-Baumann, A. O., Liedtke, C., Miederer, M., Sprenger, T., Wagner, K. J., & Miederer, I. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.074120 · Cited by 138
Martinez Botella, G., Salituro, F. G., Harrison, B. L., Beresis, R. T., Bai, Z., Blanco, M.-J., Belfort, G. M., Dai, J., Loya, C. M., Ackley, M. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00846 · Cited by 129 · cited 4×
“SAGE-217 potentiates representative examples of both synaptic and extrasynaptic GABAA receptors, preclinically differentiating it from other, currently approved GABAA receptor PAMs, such as members of the benzodiazepine class [1].”
BackgroundInfluentialSelf-citationNeurosteroids promote phosphorylation and membrane insertion of extrasynaptic GABA A receptors
Abramian, A. M., Comenencia-Ortiz, E., Modgil, A., Vien, T. N., Nakamura, Y., Moore, Y. E., Maguire, J. L., Terunuma, M., Davies, P. A., & Moss, S. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403285111 · Cited by 115
The GABA Hypothesis in Essential Tremor: Lights and Shadows
Gironell, A. (2014) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.229 · Cited by 90
Hippocampal 3α,5α-THP may alter depressive behavior of pregnant and lactating rats
Frye, C. A., & Walf, A. A. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.03.024 · Cited by 89
Modgil, A., Parakala, M. L., Ackley, M. A., Doherty, J. J., Moss, S. J., & Davies, P. A. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.10.010 · Cited by 75
Self-citationThe GABA Hypothesis in Essential Tremor: Lights and Shadows
Gironell, A. (2014) · Europe PMC (PubMed Central) · doi:10.7916/d8sf2t9c · Cited by 59
Antkowiak, B., & Rudolph, U. (2016) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000358 · Cited by 41 · cited 1×
“effects observed were anticipated and consistent with the GABAA receptor PAM mechanism of action and the pharmacologic profile of SAGE-217, with sedation observed at peak drug exposure [30].”
ResultAnticonvulsant profile of the neuroactive steroid, SGE-516, in animal models
Hammond, R., Althaus, A. L., Ackley, M. A., Maciag, C. M., Botella, G. M., Salituro, F. G., Robichaud, A. J., & Doherty, J. (2017) · Epilepsy Research · doi:10.1016/j.eplepsyres.2017.05.001 · Cited by 24
Self-citationSzodorai, E., Bampali, K., Romanov, R. A., Kasper, S. F., Hökfelt, T. G. M., Ernst, M. C., Lübec, G., & Harkany, T. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.07.003 · Cited by 11
Cited by
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“SAGE-17 GABA-A (+) allosteric modulator (180) None None GAD (179)”
BackgroundEffect of Zuranolone vs Placebo in Postpartum Depression
Deligiannidis, K. M., Meltzer-Brody, S., Gunduz-Bruce, H., Doherty, J., Jonas, J., Li, S., Sankoh, A. J., Silber, C., Campbell, A. D., Werneburg, B., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.1559 · Cited by 277
Self-citationCutler, A. J., Mattingly, G. W., & Maletic, V. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02514-2 · Cited by 194
“Zuranolone has a pharmacokinetic profile that enables oral once-daily dosing with increased bioavailability [226, 227].”
BackgroundAlthaus, A. L., Ackley, M. A., Belfort, G. M., Gee, S. M., Dai, J., Nguyen, D. P., Kazdoba, T. M., Modgil, A., Davies, P. A., Moss, S. J., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108333 · Cited by 135
“Phase 1 studies in healthy volunteers have demonstrated that zuranolone was generally well tolerated and exhibited predictable pharmacokinetics following oral administration (Hoffmann et al., 2019).”
BackgroundSelf-citationAllopregnanolone-based treatments for postpartum depression: Why/how do they work?
Walton, N., & Maguire, J. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100198 · Cited by 103
Metadata
- Authors
- Hoffmann, E., Nomikos, G. G., Kaul, I., Raines, S., Wald, J., Bullock, A., Sankoh, A. J., Doherty, J., Kanes, S. J., & Colquhoun, H.
- Affiliations
- Sage Therapeutics (United States) (US)
- Biogen (United States) (US)
- Corresponding author
- Hoffmann, Ethan
- Venue
- Clinical Pharmacokinetics
- Published
- 2019-07-24
- Volume
- 59
- Issue
- 1
- Pages
- 111-120
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC6994455
- OpenAlex
- W2963972855
- Cited by
- 59
- References
- 30
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 18 · 2023: 14 · 2022: 5 · 2021: 7 · 2020: 7 · 2019: 3
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Sage Therapeutics, Inc.
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- GABAA receptor, positive allosteric modulators, pharmacokinetics, tolerability, maximum tolerated dose, dose-finding, healthy volunteers, major depressive disorder, postpartum depression, oral bioavailability
- MeSH terms
- Administration, Oral, Adult, Allosteric Regulation, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Pharmacology, Clinical, Placebos, Pregnanes, Pregnanolone, Pyrazoles, Safety, Depression, Postpartum, GABA-A Receptor Agonists, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.